Montes Archimedes Acquisition (ROIV)
(Delayed Data from NSDQ)
$10.62 USD
-0.23 (-2.12%)
Updated Aug 1, 2024 04:00 PM ET
After-Market: $10.63 +0.01 (0.09%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ROIV 10.62 -0.23(-2.12%)
Will ROIV be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ROIV based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ROIV
Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue Estimates
Compugen (CGEN) Reports Q1 Loss, Misses Revenue Estimates
ROIV: What are Zacks experts saying now?
Zacks Private Portfolio Services
Stock Market News for Nov 14, 2023
Immunovant (IMVT) Soars on Upbeat Initial IMVT-1402 Study Data
Roivant Sciences Ltd. (ROIV) Moves 21.6% Higher: Will This Strength Last?
Other News for ROIV
Roivant to Report Financial Results for the First Quarter Ended June 30, 2024, and Provide Business Update on Thursday, August 8, 2024
3 Best Stocks to Buy Now, 7/19/2024, According to Top Analysts
Piper Sandler Keeps Their Buy Rating on Roivant Sciences (ROIV)
Buy Rating on Roivant Sciences Amid Anticipation of High-Potential Phase 2 Asset Reveal
Tracking Baker Brothers Portfolio - Q1 2024 Update